Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ravidasvir + sofosbuvir
- Development stage
- Phase 1
- Lead developer
- Drugs for Neglected Diseases initiative
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ravidasvir + sofosbuvir is an oral, fixed-dose combination of two direct-acting antiviral agents used for the treatment of chronic hepatitis C virus (HCV) infection. Ravidasvir is a pangenotypic non-structural protein 5A (NS5A) inhibitor, while sofosbuvir is a nucleotide analog inhibitor targeting the HCV NS5B RNA-dependent RNA polymerase. This combination has demonstrated high efficacy and safety in clinical trials across multiple HCV genotypes, including difficult-to-treat genotype 3 and patients with compensated cirrhosis. Developed as an affordable regimen through South-South collaboration, it aims to expand access to effective HCV therapy in low- and middle-income countries[1][2][4][5][7].
- Brand names
- Ravida
- Other names
- ravidasvir/sofosbuvirsofosbuvir/ravidasvirASC 18ASC18ASC-18
02
Targets
NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))
Beyond the preview
Go deeper on ravidasvir + sofosbuvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ravidasvir + sofosbuvir.